Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era
<h3>Aim</h3><p dir="ltr">In our study, we aim to compare the resistance profiles of <i>Acinetobacter baumannii </i>and <i>Pseudomonas aeruginosa</i> isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.</p>...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | <h3>Aim</h3><p dir="ltr">In our study, we aim to compare the resistance profiles of <i>Acinetobacter baumannii </i>and <i>Pseudomonas aeruginosa</i> isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.</p><h3>Materials</h3><p dir="ltr">The study involved adult patients monitored in the ICUs of a secondary-level hospital from January 2019 to December 2022. Isolates of <i>A. baumannii </i>and <i>P. aeruginosa </i>were obtained from blood, urine, and respiratory samples. Identification and antibiotic susceptibility tests were conducted using the disk diffusion method and the VITEK 2 system.</p><h3>Results</h3><p dir="ltr">The average age of the patients was 61.3 ± 21.9 years (range: 18–95), with a majority of 1306 (51.6%) being male. During the pandemic, <i>A. baumannii</i> isolates showed a significant increase in resistance rates for several antibiotics compared to the pre-pandemic period: imipenem (96% vs 35.1%), amikacin (84.1% vs 14.4%), ciprofloxacin (96.9% vs 36.9%), trimethoprim-sulfamethoxazole (66.4% vs 27%), and ceftazidime (96.5% vs 33.3%) (all with <i>P</i>< .001). However, there was no significant change in colistin resistance rates in these isolates (0.9% vs 0%; <i>P</i>= .307). Similarly, <i>Pseudomonas aeruginosa</i> isolates exhibited significant increases in resistance rates during the pandemic compared to the pre-pandemic period: imipenem (51.5% vs 18.8%; <i>P</i>< .001), colistin (4.9% vs 0.6%; <i>P</i>= .009), amikacin (23.5% vs 4.4%; <i>P</i>< .001), ciprofloxacin (53.3% vs 13.8%; <i>P</i>< .001), and ceftazidime (39.2% vs 12.7%; <i>P</i>< .001).</p><h3>Conclusion</h3><p dir="ltr">Our results demonstrate a significant increase in antibiotic resistance levels in <i>Acinetobacter </i>and<i> Pseudomonas</i> strains associated with hospital-acquired infections or colonization during the COVID-19 pandemic.</p><h2>Other Information</h2><p dir="ltr">Published in: Antimicrobial Stewardship & Healthcare Epidemiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1017/ash.2025.46" target="_blank">https://dx.doi.org/10.1017/ash.2025.46</a></p> |
|---|